Oppenheimer Starts Elite Pharma (ELI) at Buy
ELI Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Oppenheimer initiates coverage on Elite Pharma (AMEX: ELI) with a Buy rating and a $4.50 price target.
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Wunderlich Securities Starts Beacon Roofing Supply (BECN) at Buy
- Oppenheimer Starts LivePerson (LPSN) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
